Sanofi, Re­gen­eron hit fi­nal nail on the IL-6 re­pur­pos­ing cof­fin as Kevzara fails PhI­II

Sanofi and Re­gen­eron are putting their IL-6 pro­gram for Covid-19 to bed af­ter a piv­otal study de­liv­ered de­fin­i­tive­ly neg­a­tive re­sults.

The part­ners not­ed that the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER